Skip to Main Content

It was billed as a debate on sky-high prescription drug prices — but once again, middlemen known as pharmacy benefit managers took center stage.

A panel of policy experts and biotech veterans who gathered at Harvard on Tuesday focused much of their ire on the role of insurance. Though they disagreed on plenty — like who is ultimately responsible for high drug prices — all concluded that people would probably be better off if the health care system killed copays, which some argue gives patients “skin in the game” that can keep them from using health services or drugs they don’t need.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.